Oral bromovinyldeoxyuridine therapy for
โ
G. Tricot; Prof. E. De Clercq; M. A. Boogaerts; R. L. Verwilghen
๐
Article
๐
1986
๐
John Wiley and Sons
๐
English
โ 556 KB
Twenty-five patients with haematological diseases were treated orally with the highly potent and selective anti-herpes agent, bromovinyldeoxyuridine (BVDU), in a dosage of 7.5 mglkglday (divided over three or four doses a day) for 5 days for an intercurrent mucocutaneous herpesvirus infection. Of th